Dr. Cannon reports receiving research support and consulting fees from Arisaph Pharmaceuticals, Takeda Pharmaceuticals, Bristol-Myers Squibb, Amgen, and Merck, research support from Janssen and Daiichi Sankyo, and consulting fees from LipimetiX, Pfizer, Sanofi, Regeneron, Kowa, Alnylam, Amarin, GlaxoSmithKline, AstraZeneca, and Eisai
Dr. Bhatt, receiving research support from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi-Aventis, The Medicines Company, Roche, Pfizer, Forest Laboratories–AstraZeneca, Ischemix, Amgen, Lilly, Chiesi, and Ironwood Pharmaceuticals, fees for serving on data and safety monitoring committees and a clinical trial steering committee from Population Health Research Institute, advisory board fees from Elsevier, Medscape Cardiology, Regado Biosciences, and Cardax, fees for serving on CME steering committees from WebMD, fees for serving as site co-investigator for Biotronik and Boston Scientific, fees for serving on data and safety monitoring committees from Icahn School of Medicine at Mount Sinai
and fees for serving in various editorial roles (editor-in-chief of the Harvard Heart Letter for Belvoir Publications, chief medical editor of Cardiology Today’s Intervention for Slack Publications, editor-in-chief of the Journal of Invasive Cardiology from HMP Communications, and deputy editor of Clinical Cardiology), and participating in an unfunded research collaboration with FlowCo, PLx Pharma, Takeda, and Merck; Dr. Oldgren, receiving lecture fees and consulting fees, paid to his institution, from Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, and Sanofi
Dr. Lip, receiving lecture fees from Bayer and Roche, consulting fees from Bayer–Janssen and Biotronik, and lecture fees and consulting fees from Bristol-Myers Squibb–Pfizer, Medtronic, Boehringer Ingelheim, Microlife, and Daiichi Sankyo; Dr. Mæng, receiving advisory board fees from Bayer and AstraZeneca; Dr. Merkely, receiving grant support from Boston Scientific and Biotronik, and lecture fees from Medtronic and Terumo; Dr. Zeymer, receiving lecture fees from Novartis and Sanofi, lecture fees and consulting fees from The Medicines Company and Amgen, and grant support, lecture fees, and consulting fees from AstraZeneca; Dr. Gropper, Dr. Nordaby, Ms. Kleine, Dr. Harper, and Ms. Manassie, being employed by Boehringer Ingelheim
Dr. Januzzi, receiving grant support and consulting fees from Roche, grant support from Prevencio, Siemens, and Singulex, fees for serving on data and safety monitoring boards for Amgen, grant support and fees for serving on a clinical end-point adjudication committee for Novartis, consulting fees and fees for serving on a clinical end-point adjudication committee for Janssen, fees for serving on clinical end-point adjudication committees for Pfizer, AbbVie, and Bayer; Dr. ten Berg, receiving grant support, advisory board fees, consulting fees, and lecture fees from AstraZeneca, advisory board fees, consulting fees, and lectures fees from Eli Lilly, Daiichi Sankyo, The Medicines Company, Accumetrics, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Bayer, and grant support from ZonMw
Dr. Steg, receiving fees for serving on a steering committee from Amarin, Janssen, and CSL Behring, fees for serving on a steering committee and lecture fees from AstraZeneca, lecture fees and consulting fees from Bayer and Bristol-Myers Squibb, fees for preparation of educational material from Boehringer Ingelheim, consulting fees and fees for serving on a data and safety monitoring board from Lilly and Merck Sharpe Dohme, consulting fees from Novartis and Regeneron, fees for serving on a critical event committee from Pfizer, grant support, fees for serving on a steering committee
and consulting fees from Sanofi, and grant support, fees for serving on a steering committee, consulting fees, and fees for serving on a data and safety monitoring board from Servier; and Dr. Hohnloser, receiving consulting fees and fees for serving on a speaker bureau from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, Medtronic, and Zoll. No other potential conflict of interest relevant to this article was reported.
We thank Priscilla Driscoll Shempp, M.B.A., and Joseph M. Massaro, Ph.D., from the Baim Institute for Clinical Research for their contributions; and Dr. Martina Brückmann, Monika Simetzberger, Jens Laass, Kevin Devenny, Jon Blatchford, Herbert Noack, Sufian Chowdhury, Claudia Neumann, James Lee, Pol Mac an Mhoir, Lee Polley, Elly Carroll, and Avril Parkes from Boehringer Ingelheim for their contributions over the years, which were key to the development and conduct of the trial.